An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical … – Dove Medical Press

Yaowen Wang,¹ Xueting Hu,² Xueying Liu,³ Zengqi Wang²

¹Department of Clinical Laboratory, Weifang People’s Hospital, ²Department of Clinical Laboratory, Weifang Traditional Chinese Hospital, Weifang, ³Department of Clinical Laboratory, The 3rd Hospital of Jinan, Jinan, People’s Republic of China

Objectives: We aimed to find out the effect of sodium sugar cotransporter 2 (SGLT2) inhibitor monotherapy on the subject of glycemic and various other clinical laboratory parameters versus various other antidiabetic medications or placebo treatment in patients along with kind 2 diabetes mellitus. In addition, we aimed to investigate the danger of diabetic ketoacidosis associated along with SGLT2 inhibitor treatment and evaluate its weight-sparing ability.
Design: Meta-analysis.
Materials and methods: PubMed and MEDLINE were searched to recognize eligible studies up to December 2015. Randomized controlled trials that assessed the efficacy and safety of SGLT2 inhibitor monotherapy versus placebo treatment or energetic manage were considered. The Cochrane Collaboration danger of Bias Device was maximized to evaluate top quality and bias. The mean ­distinction was maximized to evaluate the glycemic and various other clinical laboratory parameters for SGLT2 inhibitor intervention versus manage by drugs or placebo. Similarly, the danger ratio was maximized to assess edge events, and the I² was maximized to evaluate heterogeneity.
Results: SGLT2 inhibitors considerably lessened glycated hemoglobin (HbA1c) (P<0.001), weight (P<0.001), and the low-density lipoprotein/high-density lipoprotein ratio (P=0.03) compared along with placebo therapy. No statistically substantial modifications were discovered in fasting plasma glucose, 2-hr postprandial glucose, or lipid parameters. substantial modifications in the uric acid degree were discovered for SGLT2 inhibitors versus placebo treatment (P=0.005) or energetic manage (P<0.001). Despite the fact that no substantial adjustment in levels of ketones ensued (P=0.93), patients receiving SGLT2 inhibitors were at higher danger of increased ketone bodies. Events suggestive of urinary tract infection and pollakiuria presented the greatest danger for patients receiving SGLT2 inhibitors versus energetic manage or placebo therapy.
Conclusion: SGLT2 inhibitors considerably lessened HbA1c, physique weight, and the low-density lipoprotein/high-density lipoprotein ratio and were discovered to be protected and well tolerated in kind 2 diabetes mellitus patients. Further randomized manage trials are needed to establish their danger for ketoacidosis.

Keywords: SGLT2 inhibitor, diabetic ketoacidosis, kind 2 diabetes mellitus, hyperglycemia, dyslipidemia, weight loss

This job is published and licensed by Dove Medical Press Limited. The complete terms of this license are readily available at http://ift.tt/1X6Iw1k and integrate the Creative Commons Attribution – Non Commercial (unported, v3.0) License. By accessing the job you hereby accept the Terms. Non-commercial uses of the job are allowed devoid of any kind of further permission from Dove Medical Press Limited, given the job is properly attributed. For permission for commercial usage of this work, please notice paragraphs 4.2 and 5 of our Terms.

Download Write-up [PDF]